Physician profile
Shehla Admani
NPI 1073805248
$16,043.40
in general payments reported to CMS, 2019-2025
8 companies · $16K in 2025
The $16K reported for 2025 was more than what 89% of Pediatric Dermatology providers received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.05 · 2023: $270 · 2024: $124 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $576 · Education: $22.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,421.25 |
| Food and Beverage | $576.48 |
| Education | $22.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma As | $6,971.25 | 2025 | |
| Lilly USA, LLC | $4,706.80 | 2025 | Ebglyss, Taltz |
| Arcutis Biotherapeutics, INC. | $4,019.64 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $254.05 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $28.23 | 2025 | Dupixent |
| Almirall LLC | $25.11 | 2025 | Seysara |
| Galderma Laboratories, L.P. | $23.05 | 2022 | |
| Pfizer INC. | $15.27 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shehla Admani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.